Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina

被引:22
作者
Dilernia, Dario A.
Lourtau, Leonardo
Gomez, Alejandro M.
Ebenrstejin, Juan
Toibaro, Javier J.
Bautista, Christian T.
Marone, Ruben
Carobene, Mauricio
Pampuro, Sandra
Gomez-Carrillo, Manuel
Losso, Marcelo H.
Salomon, Horacio
机构
[1] Univ Buenos Aires, Sch Med, Dept Microbiol, Natl Reference Ctr AIDS, RA-1121 Buenos Aires, DF, Argentina
[2] Hosp Gen Agudos Jose Maria Ramos Mejia, Serv Inmunocomprometidos, Buenos Aires, DF, Argentina
[3] Asociac Benef PRISMA, Lima, Peru
[4] Nexo Nongovt Gay Med Org, Buenos Aires, DF, Argentina
关键词
HIV drug resistance; surveillance; developing countries; antiretroviral access; standards for quality HIV care;
D O I
10.1097/QAD.0b013e3280b07db1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Our objective was to estimate primary resistance in an urban setting in a developing country with a long history of antiretroviral delivery and high coverage levels. Design: We carried out a resistance surveillance study according to WHO HIV-Resistance Guidelines. Methods: Blood samples were collected from 323 drug-naive HIV-1 infected individuals diagnosed at two HIV voluntary counselling and testing centers in Buenos Aires. Viral-load, CD4 cell counts and detuned assays were performed on all samples. The pol gene was sequenced and the resistance profile determined. Phylogenetic analysis was performed by neighbor-joining trees and bootscanning analysis. Results: We found that 12 (4.2%) of the 284 samples sequenced harbored primary resistance mutations, of which K103N, M41L and V1081 were most prevalent. Phylogenetic analysis revealed evidence for the transmission of the K103N mutation among the drug-naive population. The proportion of recent infections identified by the detuned assay was 10.1%. Conclusions: Levels of primary resistance in Buenos Aires are still low, despite a long history of ARV delivery and high coverage levels. (C) 2007 Lippincott Williams & Wilkins.
引用
收藏
页码:1355 / 1360
页数:6
相关论文
共 28 条
[1]  
[Anonymous], 2003, SCAL ANT THER RES LI
[2]  
BARTLETT JG, 2006, GUIDELINESS USE ANTI
[3]  
BENNETT D, 2006, 13 C RETR OPP INF DE
[4]   Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection [J].
Brenner, BG ;
Routy, JP ;
Petrella, M ;
Moisi, D ;
Oliveira, M ;
Detorio, M ;
Spira, B ;
Essabag, V ;
Conway, B ;
Lalonde, R ;
Sekaly, RP ;
Wainberg, MA .
JOURNAL OF VIROLOGY, 2002, 76 (04) :1753-1761
[5]  
Cane P, 2005, BMJ-BRIT MED J, V331, P1368, DOI 10.1136/bmj.38665.534595.55
[6]  
*CDCP, 2003, MMWR-MORBID MORTAL W, V52, P329
[7]   Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain [J].
de Mendoza, C ;
Rodriguez, C ;
Colomina, J ;
Tuset, C ;
Garcia, F ;
Eiros, JM ;
Corral, A ;
Leiva, P ;
Aguero, JS ;
Torre-Cisneros, J ;
Pedreira, J ;
Viciana, I ;
del Romero, J ;
Saez, A ;
de Lejarazu, RO ;
Soriano, V .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (09) :1350-1354
[8]   Drug resistance testing provides evidence of the globalization of HIV type 1:: A new circulating recombinant form [J].
Gómez-Carrillo, M ;
Quarleri, JF ;
Rubio, AE ;
Carobene, MG ;
Dilernia, D ;
Carr, JK ;
Salomón, H .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (08) :885-888
[9]  
HALL T. A., 1999, Nucleic Acids Symp Ser, V41, P95, DOI [10.1021/bk-1999-0734.ch008, DOI 10.1021/BK-1999-0734.CH008]
[10]  
HAMILTON G, 2003, B SOBRE VIH SIDA ARG, V10, P20